THE MOBILE INSULIN TITRATION INTERVENTION PROGRAM TO TRANSITION FROM BASAL INSULIN TO A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (MITI-GLP1): USING DAILY SMS TEXT MESSAGES AND WEEKLY PHONE CALLS TO TRANSITION PRIMARY CARE PATIENTS WITH WELL-CONTROLLED TYPE 2 DIABETES FROM BASAL INSULIN TO A GLP1-RA

被引：0

作者：

Levy, Natalie K. ^{[1
]}

Nerlino, Katie ^{[1
]}

Bongalos, Sherlane B. ^{[2
]}

Dasilva, Alexis ^{[2
]}

Uzor, Chinye N. ^{[2
]}

Sonubi, Olubunmi O. ^{[2
]}

机构：

[1] NYU, Bellevue Hosp, Med, Sch Med, New York, NY USA

[2] Bellevue Hosp Ctr, Med, New York, NY USA

来源：

JOURNAL OF GENERAL INTERNAL MEDICINE | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页码：S637 / S637

页数：1

共 46 条

[41] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA)-Experienced Adults with Type 2 Diabetes (T2D) Switching to Once-Weekly (OW) Semaglutide in a Real-World Setting-SURE Program Post Hoc Analysis
Rudofsky, Gottfried
Menzen, Markus
Potier, Louis
Catarig, Andrei-Mircea
Clark, Alice
Priyadarshini, Prachi
Abreu, Cristina
DIABETES, 2023, 72
[42] Real-world impact of adding a glucagon-like peptide-1 receptor agonist compared with basal insulin on metabolic targets in adults living with type 2 diabetes and chronic kidney disease already treated with a sodium-glucose co-transporter-2 inhibitor: The Impact GLP-1 CKD study
Chu, Lisa
Bradley, Ryan M.
Auerbach, Pernille
Abitbol, Alexander
DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4674 - 4683
[43] Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
Seino, Y.
Min, K. W.
Niemoeller, E.
Takami, A.
DIABETES OBESITY & METABOLISM, 2012, 14 (10): : 910 - 917
[44] FRONTIER: FReeStyle Libre system use in Ontario among people with diabetes in the IC/ES database-Evidence from real-world practice: Patients on basal insulin, glucagon-like peptide 1 receptor agonist or oral therapies
Ratzki-Leewing, Alexandria
Harris, Stewart B.
Rabasa-Lhoret, Remi
Poon, Yeesha
DIABETES OBESITY & METABOLISM, 2025, 27 (05): : 2637 - 2646
[45] IDegLira is efficacious across baseline HbA1c categories in subjects with Type 2 diabetes uncontrolled on sulphonylurea, glucagon-like peptide-1 receptor agonist or insulin glargine U100: analyses from completed phase 3b trials
Viljoen, A.
Sorli, C. H.
Harris, S.
Jodar, E.
Lingvay, I.
Chandarana, K.
Langer, J.
Jaeckel, E.
DIABETIC MEDICINE, 2017, 34 : 163 - 163
[46] Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
Reusch, J.
Stewart, M. W.
Perkins, C. M.
Cirkel, D. T.
Ye, J.
Perry, C. R.
Reinhardt, R. R.
Bode, B. W.
DIABETES OBESITY & METABOLISM, 2014, 16 (12): : 1257 - 1264

← 1 2 3 4 5 →